Joyce F Liu1, Jung-Min Lee1, Ellie Strock1, Ruth Phillips1, Karine Mari1, Bill Killiam1, Matthew Bonam1, Tsveta Milenkova1, Elise C Kohn1, S Percy Ivy1. 1. Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom.
Abstract
PURPOSE: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. PATIENTS AND METHODS: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed. RESULTS: Sixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea. CONCLUSION: The eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience.
PURPOSE: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. PATIENTS AND METHODS: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed. RESULTS: Sixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea. CONCLUSION: The eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience.
Authors: Kathi H Mooney; Susan L Beck; Robert H Friedman; Ramesh Farzanfar; Bob Wong Journal: Support Care Cancer Date: 2014-04-01 Impact factor: 3.603
Authors: Peter Mulders; Robert Hawkins; Paul Nathan; Igle de Jong; Susanne Osanto; Emilio Porfiri; Andrew Protheroe; Carla M L van Herpen; Bijoyesh Mookerjee; Laura Pike; Juliane M Jürgensmeier; Martin E Gore Journal: Eur J Cancer Date: 2012-01-28 Impact factor: 9.162
Authors: N Kearney; L McCann; J Norrie; L Taylor; P Gray; M McGee-Lennon; M Sage; M Miller; R Maguire Journal: Support Care Cancer Date: 2008-10-25 Impact factor: 3.603
Authors: Srikala S Sridhar; Mary J Mackenzie; Sebastien J Hotte; Som D Mukherjee; Ian F Tannock; Nevin Murray; Christian Kollmannsberger; Masoom A Haider; Eric X Chen; Robert Halford; Lisa Wang; S Percy Ivy; Malcolm J Moore Journal: Invest New Drugs Date: 2013-01-26 Impact factor: 3.850
Authors: Ursula A Matulonis; Suzanne Berlin; Percy Ivy; Karin Tyburski; Carolyn Krasner; Corrine Zarwan; Anna Berkenblit; Susana Campos; Neil Horowitz; Stephen A Cannistra; Hang Lee; Julie Lee; Maria Roche; Margaret Hill; Christin Whalen; Laura Sullivan; Chau Tran; Benjamin D Humphreys; Richard T Penson Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Joel Nathan Fishbein; Lauren Ellen Nisotel; James John MacDonald; Nicole Amoyal Pensak; Jamie Michele Jacobs; Clare Flanagan; Kamal Jethwani; Joseph Andrew Greer Journal: JMIR Res Protoc Date: 2017-04-20
Authors: Heather S L Jim; Aasha I Hoogland; Naomi C Brownstein; Anna Barata; Adam P Dicker; Hans Knoop; Brian D Gonzalez; Randa Perkins; Dana Rollison; Scott M Gilbert; Ronica Nanda; Anders Berglund; Ross Mitchell; Peter A S Johnstone Journal: CA Cancer J Clin Date: 2020-04-20 Impact factor: 508.702
Authors: William Goodman; Anne-Marie Bagnall; Laura Ashley; Desiree Azizoddin; Felix Muehlensiepen; David Blum; Michael I Bennett; Matthew Allsop Journal: JMIR Cancer Date: 2022-02-17